Status:
COMPLETED
Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia
Lead Sponsor:
Institute of Tropical Medicine, Belgium
Collaborating Sponsors:
Wollo University
Boru Meda Hospital
Conditions:
Cutaneous Leishmaniasis
Eligibility:
All Genders
Brief Summary
Outcomes of patients receiving SSG and Allopurinol combination have never been documented systematically in Ethiopia. Therefore, it is not known how effective this combination is. This study will prov...
Detailed Description
Cutaneous Leishmaniasis (CL) in Ethiopia causes severe dermatological mutilations. Forms that require systemic treatment are complicated localized cutaneous leishmaniasis (cLCL), mucocutaneous leishma...
Eligibility Criteria
Inclusion
- Clinically or microscopically confirmed diagnosis of MCL, DCL or complicated LCL
- Clinical routine care decision to initiate systemic CL treatment using SSG with allopurinol
- Willing and able to provide informed consent
Exclusion
- Medical emergencies, underlying chronic conditions or other circumstances that make participation in this study medically or otherwise inadvisable
- Study sample collection only for Age 18 and above
Key Trial Info
Start Date :
February 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2022
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT04699383
Start Date
February 15 2021
End Date
December 15 2022
Last Update
March 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boru Meda Hospital
Dessie, Ethiopia